| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 1456 | 2018 |
| The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity CL Addison, TO Daniel, MD Burdick, H Liu, JE Ehlert, YY Xue, L Buechi, ... The Journal of Immunology 165 (9), 5269-5277, 2000 | 749 | 2000 |
| A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis SR Wiley, L Cassiano, T Lofton, T Davis-Smith, JA Winkles, V Lindner, ... Immunity 15 (5), 837-846, 2001 | 494 | 2001 |
| Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis TO Daniel, H Liu, JD Morrow, BC Crews, LJ Marnett Cancer research 59 (18), 4574-4577, 1999 | 431 | 1999 |
| Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ... Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020 | 359 | 2020 |
| Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677, 2021 | 334 | 2021 |
| Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis N Cheng, DM Brantley, H Liu, Q Lin, M Enriquez, N Gale, G Yancopoulos, ... Molecular Cancer Research 1 (1), 2-11, 2002 | 311 | 2002 |
| Surface densities of ephrin‐B1 determine EphB1‐coupled activation of cell attachment through αvβ3 and α5β1 integrins U Huynh‐Do, E Stein, AA Lane, H Liu, DP Cerretti, TO Daniel The EMBO journal, 1999 | 270 | 1999 |
| Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis U Huynh-Do, C Vindis, H Liu, DP Cerretti, JT McGrew, M Enriquez, ... Journal of cell science 115 (15), 3073-3081, 2002 | 203 | 2002 |
| Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial IK Mellinghoff, M Penas-Prado, KB Peters, HA Burris III, EA Maher, ... Clinical Cancer Research 27 (16), 4491-4499, 2021 | 189 | 2021 |
| Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations EC Dees, RB Cohen, M von Mehren, TE Stinchcombe, H Liu, ... Clinical cancer research 18 (17), 4775-4784, 2012 | 182 | 2012 |
| Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or … UA Matulonis, S Sharma, S Ghamande, MS Gordon, SA Del Prete, ... Gynecologic oncology 127 (1), 63-69, 2012 | 172 | 2012 |
| Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ... Blood advances 4 (9), 1894-1905, 2020 | 163 | 2020 |
| Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma OA O’Connor, M Özcan, ED Jacobsen, JM Roncero, J Trotman, J Demeter, ... Journal of Clinical Oncology 37 (8), 613-623, 2019 | 129 | 2019 |
| Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors N Cheng, D Brantley, WB Fang, H Liu, W Fanslow, DP Cerretti, ... Neoplasia 5 (5), 445-456, 2003 | 129 | 2003 |
| AMG 595, an anti-EGFRvIII antibody–drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma KJ Hamblett, CJ Kozlosky, S Siu, WS Chang, H Liu, IN Foltz, ... Molecular cancer therapeutics 14 (7), 1614-1624, 2015 | 104 | 2015 |
| Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics T Macarulla, A Cervantes, E Elez, E Rodríguez-Braun, J Baselga, ... Molecular cancer therapeutics 9 (10), 2844-2852, 2010 | 96 | 2010 |
| A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism Z Liu, EC Leng, K Gunasekaran, M Pentony, M Shen, M Howard, J Stoops, ... Journal of Biological Chemistry 290 (12), 7535-7562, 2015 | 95 | 2015 |
| Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress J Du, J Luan, H Liu, TO Daniel, S Peiper, TS Chen, Y Yu, LW Horton, ... Journal of leukocyte biology 71 (1), 141-153, 2002 | 88 | 2002 |
| Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors EC Dees, JR Infante, RB Cohen, BH O’Neil, S Jones, M Von Mehren, ... Cancer chemotherapy and pharmacology 67, 945-954, 2011 | 87 | 2011 |
